Abstract
Poly(lactic-co-glycolic acid) (PLGA) particles carrying antigen and adjuvant is a promising vaccine system which has been shown to stimulate systemic antigen-specific immune responses. In this study, we investigated the relationship of (i) the sizes of PLGA particle and (ii) the presence of cytosine-phosphate-guanine motifs (CpG), with the extent and type of immune response stimulated against Dermatophagoides pteronyssinus-2 (Der p2) antigen. Different sizes of PLGA particles encapsulating CpG were prepared using a double emulsion solvent evaporation method. Mice were vaccinated with Der p2 and different sizes of empty or CpG-loaded PLGA particles. Vaccinated mice were exposed to daily intranasal instillation of Der p2 for 10 days followed by euthanization to estimate leukocyte accumulation in bronchoalveolar lavage (BAL) fluids, antibody profiles, and airway hyperresponsiveness. PLGA particles showed a size-dependent decrease in the proportion of eosinophils found in BAL fluids. Mice vaccinated with the Der p2 coated on 9-μm-sized empty PLGA particles showed increased levels of IgE and IgG1 antibodies as well as increased airway hyperresponsiveness. All sizes of PLGA particles encapsulating CpG prevented airway hyperresponsiveness after Der p2 exposures. Inflammatory responses to Der p2 exposure were significantly reduced when smaller PLGA particles were used for vaccination. In addition, encapsulating CpG in PLGA particles increased IgG2a secretion. This study shows that the size of PLGA particles used for vaccination plays a major role in the prevention of house dust mite-induced allergy and that incorporation of CpG into the PLGA particles preferentially develops a Th1-type immune response.
Similar content being viewed by others
References
Arbes Jr SJ, Cohn RD, Yin M, Muilenberg ML, Burge HA, Friedman W, et al. House dust mite allergen in US beds: results from the First National Survey of lead and allergens in housing. J Allergy Clin Immunol. 2003;111(2):408–14.
Busse WW, Lemanske Jr RF. Asthma. N Engl J Med. 2001;344(5):350–62.
Lambrecht BN, Hammad H. The airway epithelium in asthma. Nat Med. 2012;18(5):684–92.
Johnson JR, Wiley RE, Fattouh R, Swirski FK, Gajewska BU, Coyle AJ, et al. Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling. Am J Respir Crit Care. 2004;169(3):378–85.
Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108(2):E36.
Barnes PJ. Severe asthma: advances in current management and future therapy. J Allergy Clin Immunol. 2012;129(1):48–59.
Incorvaia C, Di Rienzo A, Celani C, Makri E, Frati F. Treating allergic rhinitis by sublingual immunotherapy: a review. Ann Ist Super Sanita. 2012;48(2):172–6.
Eifan AO, Akkoc T, Yildiz A, Keles S, Ozdemir C, Bahceciler NN, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy. 2010;40(6):922–32.
Eifan AO, Calderon MA, Durham SR. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther. 2013;13(11):1543–56.
Mazzarella G, Bianco A, Catena E, De Palma R, Abbate GF. Th1/Th2 lymphocyte polarization in asthma. Allergy. 2000;55:6–9.
Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol. 1999;17:255–81.
Wohlleben G, Erb KJ. Atopic disorders: a vaccine around the corner? Trends Immunol. 2001;22(11):618–26.
Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131(5):1288–96 e3.
Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1–55.
Arlian LG, Morgan MS, Neal JS. Dust mite allergens: ecology and distribution. Curr Allergy Asthma Rep. 2002;2(5):401–11.
Kidon MI, Chiang WC, Liew WK, Ong TC, Tiong YS, Wong KN, et al. Mite component-specific IgE repertoire and phenotypes of allergic disease in childhood: the tropical perspective. Pediatr Allergy Immunol. 2011;22(2):202–10.
Trompette A, Divanovic S, Visintin A, Blanchard C, Hegde RS, Madan R, et al. Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature. 2009;457(7229):585–8.
Trombone APF, Tobias KRC, Ferriani VPL, Schuurman J, Aalberse RC, Smith AM, et al. Use of a chimeric ELISA to investigate immunoglobulin E antibody responses to Der p 1 and Der p 2 in mite-allergic patients with asthma, wheezing and/or rhinitis. Clin Exp Allergy. 2002;32(9):1323–8.
Tan LK, Huang CH, Kuo IC, Liew LM, Chua KY. Intramuscular immunization with DNA construct containing Der p 2 and signal peptide sequences primed strong IgE production. Vaccine. 2006;24(29–30):5762–71.
Huang TJ, MacAry PA, Eynott P, Moussavi A, Daniel KC, Askenase PW, et al. Allergen-specific Th1 cells counteract efferent Th2 cell-dependent bronchial hyperresponsiveness and eosinophilic inflammation partly via IFN-gamma. J Immunol. 2001;166(1):207–17.
Kline JN, Krieg AM. Toll-Like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Drug News Perspect. 2008;21(8):434–9.
Fonseca DE, Kline JN. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv Drug Deliv Rev. 2009;61(3):256–62.
Pulsawat P, Pitakpolrat P, Prompetchara E, Kaewamatawong T, Techakriengkrai N, Sirivichayakul S, et al. Optimization of a Der p 2-based prophylactic DNA vaccine against house dust mite allergy. Immunol Lett. 2013;151(1–2):23–30.
Heeg K, Zimmermann S. CpG DNA as a Th1 trigger. Int Arch Allergy Immunol. 2000;121(2):87–97.
Mo JH, Park SW, Rhee CS, Takabayashi K, Lee SS, Quan SH, et al. Suppression of allergic response by CpG motif oligodeoxynucleotide-house-dust mite conjugate in animal model of allergic rhinitis. Am J Rhinol. 2006;20(2):212–8.
Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol. 2004;113(6):1144–51.
Kaburaki Y, Fujimura T, Kurata K, Masuda K, Toda M, Yasueda H, et al. Induction of Th1 immune responses to Japanese cedar pollen allergen (Cry j 1) in mice immunized with Cry j 1 conjugated with CpG oligodeoxynucleotide. Comp Immunol Microbiol Infect Dis. 2011;34(2):157–61.
Shirota H, Sano K, Kikuchi T, Tamura G, Shirato K. Regulation of T-helper type 2 cell and airway eosinophilia by transmucosal coadministration of antigen and oligodeoxynucleotides containing CpG motifs. Am J Respir Cell Mol. 2000;22(2):176–82.
Gomez JMM, Fischer S, Csaba N, Kundig TM, Merkle HP, Gander B, et al. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles. Pharm Res. 2007;24(10):1927–35.
Scholl I, Kopp T, Bohle B, Jensen-Jarolim E. Biodegradable PLGA particles for improved systemic and mucosal treatment of Type I allergy. Immunol Allergy Clin N Am. 2006;26(2):349–64. ix.
Martinez Gomez JM, Fischer S, Csaba N, Kundig TM, Merkle HP, Gander B, et al. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles. Pharm Res. 2007;24(10):1927–35.
Zhang XQ, Dahle CE, Baman NK, Rich N, Weiner GJ, Salem AK. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. J Immunother. 2007;30(5):469–78.
Joshi VB, Geary SM, Salem AK. Biodegradable particles as vaccine delivery systems: size matters. AAPS J. 2013;15(1):85–94.
Thorne PS, McCray PB, Howe TS, O'Neill MA. Early-onset inflammatory responses in vivo to adenoviral vectors in the presence or absence of lipopolysaccharide-induced inflammation. Am J Respir Cell Mol. 1999;20(6):1155–64.
George CL, White ML, Kulhankova K, Mahajan A, Thorne PS, Snyder JM, et al. Early exposure to a nonhygienic environment alters pulmonary immunity and allergic responses. Am J Physiol Lung Cell Mol Physiol. 2006;291(3):L512–22.
De S, Robinson DH. Particle size and temperature effect on the physical stability of PLGA nanospheres and microspheres containing Bodipy. AAPS PharmSciTech. 2004;5(4):e53.
Gregory LG, Lloyd CM. Orchestrating house dust mite-associated allergy in the lung. Trends Immunol. 2011;32(9):402–11.
Wang X, Yang Q, Wang P, Luo L, Chen Z, Liao B, et al. Derp2-mutant gene vaccine inhibits airway inflammation and up-regulates Toll-like receptor 9 in an allergic asthmatic mouse model. Asian Pac J Allergy Immunol. 2010;28(4):287–93.
Daan de Boer J, Roelofs JJ, de Vos AF, de Beer R, Schouten M, Hommes TJ, et al. Lipopolysaccharide inhibits Th2 lung inflammation induced by house dust mite allergens in mice. Am J Respir Cell Mol. 2013;48(3):382–9.
Sumino K, Sugar EA, Irvin CG, Kaminsky DA, Shade D, Wei CY, et al. Methacholine challenge test: diagnostic characteristics in asthmatic patients receiving controller medications. J Allergy Clin Immunol. 2012;130(1):69–75 e6.
Akinbami LJ, Moorman JE, Bailey C, Zahran HS, King M, Johnson CA, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001–2010. NCHS Data Brief. 2012;94:1–8.
Bharadwaj AS, Bewtra AK, Agrawal DK. Dendritic cells in allergic airway inflammation. Can J Physiol Pharmacol. 2007;85(7):686–99.
Suzuki K, Kaminuma O, Yang L, Takai T, Mori A, Umezu-Goto M, et al. Prevention of allergic asthma by vaccination with transgenic rice seed expressing mite allergen: induction of allergen-specific oral tolerance without bystander suppression. Plant Biotechnol J. 2011;9(9):982–90.
Kündig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A, et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol. 2006;117(6):1470–6.
Standley SM, Mende I, Goh SL, Kwon YJ, Beaudette TT, Engleman EG, et al. Incorporation of CpG oligonucleotide ligand into protein-loaded particle vaccines promotes antigen-specific CD8 T-cell immunity. Bioconjug Chem. 2007;18(1):77–83.
O'Hagan DT, Rappuoli R. Novel approaches to pediatric vaccine delivery. Adv Drug Deliv Rev. 2006;58(1):29–51.
Shen J, Burgess DJ. Drugs for long acting injections and implants. In: Wright JC, Burgess DJ, editors. Long acting injections and implants. New York: Springer; 2012. p. 73–92.
Hamdy S, Haddadi A, Hung RW, Lavasanifar A. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev. 2011;63(10–11):943–55.
Scholl I, Weissenbock A, Forster-Waldl E, Untersmayr E, Walter F, Willheim M, et al. Allergen-loaded biodegradable poly (D, L-lactic-co-glycolic) acid nanoparticles down-regulate an ongoing Th2 response in the BALB/c mouse model. Clin Exp Allergy. 2004;34(2):315–21.
Senti G, Johansen P, Haug S, Bull C, Gottschaller C, Müller P, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy. 2009;39(4):562–70.
van Ree R, Antonicelli L, Akkerdaas JH, Garritani MS, Aalberse RC, Bonifazi F. Possible induction of food allergy during mite immunotherapy. Allergy. 1996;51(2):108–13.
Bosnjak B, Stelzmueller B, Erb KJ, Epstein MM. Treatment of allergic asthma: modulation of Th2 cells and their responses. Respir Res. 2011;12:114.
Tang MLK, Powell CVE. Childhood asthma as an allergic disease: rationale for the development of future treatment. Eur J Pediatr. 2001;160(12):696–704.
Pulsawat P, Pitakpolrat P, Prompetchara E, Kaewamatawong T, Techakriengkrai N, Sirivichayakul S, et al. Optimization of a Der p 2-based prophylactic DNA vaccine against house dust mite allergy. Immunol Lett. 2013;151(1–2):23–30.
Zhang F, Huang G, Hu B, Song Y, Shi Y. Induction of immune tolerance in asthmatic mice by vaccination with DNA encoding an allergen-cytotoxic T lymphocyte-associated antigen 4 combination. Clin Vaccine Immunol: CVI. 2011;18(5):807–14.
Acknowledgments
The authors gratefully acknowledge support from the National Institute of Environmental Health Sciences-funded Environmental Health Sciences Research Center (NIH P30 ES005605). Other sources of support include the American Cancer Society (RSG-09-015-01-CDD), the National Cancer Institute (NIH 1R21CA13345-01/1R21CA128414-01A2/UI Mayo Clinic Lymphoma SPORE), and the Lyle and Sharon Bighley Professorship. We thank Sean Geary for expert reading of the manuscript.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Guest Editor: Aliasger K. Salem
Vijaya B. Joshi, Andrea Adamcakova-Dodd, and Xuefang Jing contributed equally to this work.
Rights and permissions
About this article
Cite this article
Joshi, V.B., Adamcakova-Dodd, A., Jing, X. et al. Development of a Poly (lactic-co-glycolic acid) Particle Vaccine to Protect Against House Dust Mite Induced Allergy. AAPS J 16, 975–985 (2014). https://doi.org/10.1208/s12248-014-9624-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-014-9624-5